Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.
McGill University, Montreal, QC, Canada.
Paul S
PS
Giacomini
Ayal
A
Rozenberg
Imke
I
Metz
David
D
Araujo
Nathalie
N
Arbour
Amit
A
Bar-Or
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000188:drug therapy* / Q000821:virology; D016867:Immunocompromised Host; D007577:JC Virus; D007968:Leukoencephalopathy, Progressive Multifocal / Q000188:drug therapy* / Q000209:etiology; D000077592:Maraviroc; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000188:drug therapy; D000069442:Natalizumab; D019713:Receptors, CCR5 / Q000276:immunology; D014230:Triazoles / Q000627:therapeutic use*; D019562:Viral Load
D061067:Antibodies, Monoclonal, Humanized; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D000069442:Natalizumab; D019713:Receptors, CCR5; D014230:Triazoles; D000077592:Maraviroc